Navigation Links
Allegheny Health Network Team Develops Biomarker for Early Detection of Esophageal Cancer

PITTSBURGH, PA (PRWEB) August 06, 2014

A research team led by Allegheny Health Network surgical oncologist Blair Jobe, MD, has developed and validated a four-protein serum biomarker panel that holds significant promise for early detection of esophageal cancer, a relatively rare but often deadly disease that has grown in incidence over the past several decades.

Dr. Jobe’s findings were published online today in Cancer, a journal of the American Cancer Society.

The four-protein panel, called B-AMP (biglycan, myeloperoxidase, annexin-A6 and protein S100-A9), is a simple, non-invasive, low-cost blood test, that identified esophageal cancer with a high classification accuracy of 87 percent in the study.

The discovery represents a major step forward in not only early detection but also the management of esophageal cancer, said Dr. Jobe, Director of Allegheny Health Network’s Esophageal and Thoracic Institute. The test is already being used at the Institute in a clinical trial setting to monitor the course of esophageal cancer, providing physicians with guidance on response to therapy or early notification of a recurrence and allowing them to pursue different or more aggressive therapies, if necessary.

“Esophageal cancer patients often have few options available to fight this disease, and five-year survival rates are extremely low at about 15 percent,” said Dr. Jobe. “We’ve made progress in treating and monitoring patients with conditions that can progress to esophageal cancer, such as Gastroesophageal Reflux Disease (GERD), Barrett’s Esophagus and high-grade dysplasia. Yet only a small minority of these patients develop life-threatening esophageal cancer. Better detection techniques are needed to identify the patients who will likely progress from these precursor lesions to cancer.”

The incidence of esophageal cancer is rapidly rising: up to 600 percent higher than in the 1970s. Survival is better when the disease is detected early, but unfortunately most patients do not sense difficulty swallowing until a tumor is advanced, making the development of biomarkers for the cancer critically important.

“We are excited and very optimistic about how this biomarker panel could be used to help patients, from early detection in at-risk patients, to risk-monitoring for patients with conditions that may lead to esophageal cancer, to monitoring the disease course in patients with cancer, adjusting their surveillance and treatment and potentially extending their lives,” said Ali Zaidi, MD, Director of Research at the AHN Esophageal and Thoracic Institute.

The development of blood-based biomarkers has improved early detection and impacted treatment of cancers such as ovarian and prostate, but development of blood-based esophageal cancer biomarkers has been hampered by the difficulty in identifying a single conserved and universal tracking marker.

Using tissue data from the esophageal cancer progression sequence, biomarkers having known cancer relevance and which are upregulated, were selected for testing in the serum. Followed by novel mathematical modeling, Dr. Jobe’s team was able to combine relevant and strong individual biomarkers into a panel that is accurate and reliable in detecting esophageal cancer.

The team used tissue samples obtained from the Department of Pathology at the University of Pittsburgh, representing patients with Barrett’s Esophagus, high-grade dysplasia and esophageal cancer; for identifying and selecting targets for blood testing using a global proteomics profiling platform. The candidate biomarkers were then tested in blood samples from patients with non-Barrett’s esophagus GERD and esophageal cancer. The findings were validated in an independent but similar cohort assembled at Allegheny Health Network and Roswell Park Cancer Institute in Buffalo.

Out of 3,777 identified tissue proteins, five were shown to have significantly elevated levels in blood of patients with esophageal cancer, as compared to those with non-Barrett’s esophagus GERD, and on mathematical modeling four of those five were shown to have predictive value.

Potential future uses for the protein biomarker assay include screening high-risk patients such as those with obesity and GERD, monitoring disease progression from Barrett’s esophagus to high-risk dysplasia to esophageal cancer, tracking a patient’s response to therapy and enabling therapy tailored to a patient’s individual disease biology and detecting recurrence prior to clinical imaging.

“Dr. Jobe’s research shows the value of our approach to working collaboratively and across the full spectrum of disease,” said David Parda, MD, System Chair, Allegheny Health Network Cancer Institute. “This tour de force research integrates clinical work and advanced biology/informatics to improve prevention, treatment, prognostic and predictive capabilities.”

Researchers from the Academic Medical Center in Amsterdam also participated in the study.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study by Allegheny General Hospital Physicians Shows Oral Immunotherapy is a Safe, Effective Alternative to Allergy Shots for Ragweed Sufferers
2. West Penn Allegheny Health System is First in Pennsylvania to Perform Groundbreaking Minimally-Invasive Procedure for Swallowing Disorder
3. West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough
4. Allegheny Health Network Allergist Opposes OTC Sales of Corticosteroids in FDA Testimony, Citing Safety Concerns
5. Allegheny Health Network Becomes Official Medical Provider for Robert Morris University Athletic Program
6. Allegheny Health Network’s LifeFlight Marks 35th Year
7. Allegheny Health Network Partners with Region’s EMS Providers to Advance Treatment of Heart Attack Patients
8. Allegheny General Hospital Streamlines Testing for Liver Transplant Patients with Advanced Cardiac MRI
9. Allegheny Health Network Psychologist among Panelists at Senate Staff Briefing In Support of Legislation to Help Patients with Mental Health, Addiction Disorders
10. Four Allegheny Health Network Hospitals Named High Performers by U.S. News
11. Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to ... for dental implants at her Mississauga, ON practice. Dr. Williams has been ... placement of dental implants. , Missing teeth can lead to a variety of ...
(Date:11/24/2015)... ... , ... In an article published November 12th by Obesity News ... or are not eligible for bariatric surgery. The article explains that candidates for weight ... 100 pounds overweight, or have a BMI of 35 and over with at least ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Preparing for the ... – 3:00 p.m. EST, , FDA has long asserted that design ... apply to performing the tests and do not meet the device regulations. , Come ...
(Date:11/24/2015)... FL (PRWEB) , ... November 24, 2015 , ... In ... a growing epidemic as deaths from prescription opioids in the United States grew 400 ... cocaine. In 2013 alone, opioids were involved in 37 percent of all fatal drug ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the nation’s leading ... holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic is designed ... way. The location is scheduled to operate through Dec. 24. , Holiday Pop-Up Clinic ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... the addition of the  "Global Drug ...  report to their offering.  --> ... addition of the  "Global Drug Device ... to their offering.  --> ...
(Date:11/24/2015)... -- The hope of bearing a child ... cycles. After failure of over 15 IVF cycles, Mrs. ... hopes that she would be able to conceive ever. But finally optimism prevailed as she ... of over 15 IVF cycles. India ... one last attempt with Gaudium IVF Center in New ...
(Date:11/24/2015)... Nov. 25, 2015 WuXi PharmaTech (Cayman) Inc. ... leading open-access R&D capability and technology platform company serving ... in China and ... an extraordinary general meeting of shareholders held today, the ... authorize and approve the previously announced agreement and plan ...
Breaking Medicine Technology: